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The Breast Cancer Resistance Protein (BCRP/ABCG2) is a
transporter restricting absorption and enhancing excretion of
many compounds including anticancer drugs. This
transporter is highly expressed in many tissues; however, in
human kidney, only the mRNA was found in contrast to
the mouse kidney, where the transporter is abundant. In
bcrp/abcg2(/) mice, the expression of two sterol transporter
genes, abcg5 and abcg8, was strongly increased in the
kidney, perhaps as a compensatory mechanism to upregulate
efflux. We found using immunohistochemical analysis clear
localization of BCRP/ABCG2 to the proximal tubule brush
border membrane of the human kidney comparable to that
of other ABC transporters such as P-glycoprotein/ABCB1,
MRP2/ABCC2, and MRP4/ABCC4. Hoechst 33342 dye efflux
from primary human proximal tubule cells was significantly
reduced by the BCRP/ABCG2 inhibitors fumitremorgin C and
nelfinavir. Our study shows that in addition to other apical
ABC transporters, BCRP/ABCG2 may be important in renal
drug excretion.
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Breast Cancer Resistance Protein (BCRP/ABCG2) is a
member of the ATP-binding cassette (ABC) drug transporter
family, which was first discovered in a multidrug-resistant
breast cancer cell line. BCRP/ABCG2 is a half-transporter and
functions most likely as a homodimer that actively effluxes its
substrates across the cell membrane. In recent years,
much more information has become available about the
function of BCRP/ABCG2 and its substrates. BCRP/ABCG2
can transport a functionally and structurally highly diverse
range of substrates, like chemotherapeutics (mitoxantrone,
topotecan), nucleoside analogs (lamivudine), fluorophores
(rhodamine 123, Hoechst 33342), conjugated anions (estrone-
3-sulfate, DHEAS), flavanoids (genistein), folates (folic acid),
riboflavin (vitamin B12), and porphyrins (heme).
1–4
BCRP/ABCG2 is expressed in plasma membranes of
different tissues with an important barrier function, like the
apical membrane of the small and large intestines, the
canalicular membrane of hepatocytes, the luminal membrane
of the capillary endothelium of the brain, and in the brush
border membrane of placental syncytiotrophoblasts.5 In
addition, BCRP/ABCG2 is expressed in the mammary gland
of humans, mice, and cows,6 where the efflux pump is highly
upregulated during lactation. This augmented expression is
responsible for the active secretion of vitamins into milk, but
is also accompanied by the secretion of potentially harmful
compounds, like carcinogens, dietary toxins, and drugs,
into milk.
There is an extensive overlap in substrate specificity and
localization on barrier epithelia between BCRP/ABCG2 and
other multidrug transporters, like multidrug resistance
protein 2 (MRP2/ABCC2) and P-glycoprotein (P-gp/
ABCB1), suggesting a complementary role for the efflux
pumps. Surprisingly, however, not much is known about the
expression levels of BCRP/ABCG2 in human kidney. In
healthy human tissue, low mRNA expression levels were
found and the transporter protein itself was undetectable.7,8
Renal carcinoma samples showed a moderate BCRP/ABCG2
expression,9 although with the use of a different antibody,
no expression in carcinoma tissue has been reported as well.10
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In contrast, mouse kidney tissue showed a high mRNA
expression,11 and immunohistochemistry demonstrated a
clear staining of bcrp/abcg2 in the apical membrane of the
cortical proximal tubules,12 which was strongly induced after
ischemia reperfusion injury.11 This increased expression
supports the hypothesis that BCRP/ABCG2 plays a role in
renal regeneration after injury.
In the present study, we investigated the gene and protein
expression of BCRP/ABCG2 in human kidney, using the
antibody BXP-9. We performed western blot analysis and
immunohistochemistry, and compared the expression levels
in human kidney tissue with that in rat and mouse kidney
samples. Furthermore, we determined the functional activity
of BCRP/ABCG2 in human kidney cells.
RESULTS
In mouse kidney, high gene and protein expression levels
of bcrp were found.11 In this study, we compared gene
expression levels of 36 ABC transporters in bcrp(/) mouse
kidney with the levels in FVB mouse (wild type) kidney
(Figure 1). Several transporters, like abca5, abcb4, abcc2, and
abcc4, were significantly up- or downregulated in the
knockout mice. But the most pronounced differential
expression was found for the subfamily members, abcg5
and abcg8, which showed a 20- to 100-fold upregulation
in bcrp(/) mice.
In contrast to mouse kidney, not much is known about
BCRP expression and localization in the human kidney. We
compared expression levels of ABCG2 in human kidney with
expression levels in rat and mouse kidney (Table 1). After
performing quantitative real-time (RQ)-PCR using healthy
human kidney samples, we found a moderate expression of
BCRP/ABCG2 mRNA. In rodent kidney, mRNA levels were
clearly higher as compared to human kidney, with highest
expression in the mouse. Furthermore, BCRP/ABCG2 gene
expression levels appeared somewhat lower than the mRNA
0
1
In
du
ct
io
n 
fo
ld
0
1
2
3
4
5
6
In
du
ct
io
n 
fo
ld
0
0
10
20
100
200
0
1
2
1
2
3
4
5
6
7
8
9
abcc
abcg
abcd
In
du
ct
io
n 
fo
ld
In
du
ct
io
n 
fo
ld
In
du
ct
io
n 
fo
ld
2
3
abca abcb
* **
*
*
***
***
***
*
*
*
***
***
***
**
**
**
ab
ca
1
ab
ca
2
ab
ca
3
ab
ca
4
ab
ca
5
ab
ca
6
ab
ca
7
ab
ca
8a
ab
ca
8b
ab
ca
9
ab
cc1
ab
cc2
ab
cc3
ab
cc4
ab
cc5
ab
cc8
ab
cc9
ab
cc1
0
ab
cg
1
ab
cg
3
ab
cg
4
ab
cg
5
ab
cg
8
ab
cd
1
ab
cd
2
ab
cd
3
ab
cd
4
ab
cb
1a
ab
cb
1b
ab
cb
2
ab
cb
3
ab
cb
4
ab
cb
6
ab
cb
9
ab
cb
10
ab
cb
11
a b
c
e
d
Figure 1 | Quantitative real-time (RQ)-PCR analysis of ABC transporters in bcrp/abcg2(/) mouse kidney. Gene expression of ABC
transporters from the abca (a), abcb (b), abcc (c), abcd (d), and abcg (e) subfamilies was determined in bcrp/abcg2(/) mice and FVB (wild type)
mice. The induction fold indicates up- or downregulation of the various transporters in bcrp/abcg2(/) mice compared to FVB mice.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal standard for normalization of gene expression levels
(CT values for GAPDH: FVB mouse¼ 19.8±0.3, bcrp/abcg2(/) mouse¼ 19.7±0.1). *Po0.05, **Po0.01, ***Po0.001, compared to FVB mice.
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expression levels of other apically expressed ABC transpor-
ters, for example, ABCB1/P-glycoprotein (Po0.01), ABCC2/
MRP2, and ABCC4/MRP4 in human kidney (not significant)
(Table 1). Recently, we reported that primary cultures of
human proximal tubule cells grown as monolayers on
permeable filter supports, retained a full palette of proximal
tubule transport proteins, and provide a powerful model to
study the mechanisms and regulation of xenobiotic trans-
port, particularly apical efflux transporters.13 In agreement
with the RQ-PCR results, Figure 2a shows the expression of a
PCR product encoding a 206-bp fragment of BCRP in freshly
isolated human kidney cortex (lanes 4 and 5) and in the
primary cultures of tubule cells derived from this material. At
8 days in culture, we found expression of mRNA encoding
BCRP/ABCG2 in both the proximal tubule cell monolayers
(lane 2) and the mixed cell monolayers (B80% proximal,
B20% distal/collecting duct cells) (lane 3), but no expression
of BCRP/ABCG2 mRNA was detected in pure cultures of
distal/collecting duct cells (lane 6).
We investigated protein expression of BCRP/ABCG2 using
the BXP-9 antibody (Kamiya Biomedical Company, Seattle,
WA, USA). This antibody was specifically raised against mice
bcrp, but Figure 2b shows that it cross-reacts with rat and
human BCRP/ABCG2 as well. The efflux pump was detected
in isolated human total membranes (lanes 1 and 2), isolated
human proximal tubular cells (lane 9), rat kidney brush
border membranes (lanes 3 and 4), and mouse kidney total
membranes (lanes 7 and 8) were used. As a negative control,
total membranes isolated from bcrp/abcg2(/) mice were
used (lanes 5 and 6). As expected, the negative control
showed no signal. After semiquantifying the protein expres-
sion levels by measurement of pixel intensities of both BCRP/
ABCG2 and b-actin bands, we observed that the expression
of BCRP/ABCG2 was highest in mouse kidney followed by
rat kidney samples (Figure 2c). Human kidney samples
showed a moderate expression level, which is in accordance
with the expression levels measured by RQ-PCR. We could
also detect BCRP/ABCG2 in proximal tubule cells isolated
from healthy human urine samples,14 with a relative
expression comparable to the human kidney cortex sample.
Immunohistochemistry was applied to study the localiza-
tion of BCRP/ABCG2 in kidney tissue. Unlike Maliepaard
et al.,8 who used BXP-21 and BXP-34, we found a clear
staining of BCRP/ABCG2 in the human proximal tubule
brush border membranes with the BXP-9 antibody (Figure
3a). Also, in rat tissue, the efflux pump is present at the apical
side of the proximal tubules (Figure 3b), identical to the
localization in mouse and human kidney (Figure 3d). Tissue
from bcrp/abcg2(/) mouse showed no staining (Figure 3c),
which emphasizes the specificity of the antibody used.
Moreover, in polarized human primary proximal tubule
cell monolayers grown on permeable filter supports, we
found extensive staining of the cell membrane with both the
BXP-9 (Figure 4a) and BXP-21 antibodies (data not shown).
BXP-9 antibody staining was localized primarily to the apical
membrane of the monolayer with some degree of staining in
the cytoplasm just below the membrane surface (Figure 4b).
Finally, we tested the functional expression of BCRP/
ABCG2 in monolayers of primary proximal tubule cells using
Table 1 | ABC transporter gene expression in the kidney of
three different species
ABC transporter, gene
symbols
DCT values
Human
kidney
Mouse
kidney Rat kidney
ABCG2 6.9±0.7 2.20±0.08*** 4.1±0.2*
ABCB1/Abcb1a 4.1±0.4 9.21±0.03*** 8.41±0.01***
Abcb1b 11.0±0.4*** 10.83±0.08***
ABCC2 5.1±0.4 4.09±0.03* 6.7±0.3**
ABCC4 4.9±0.4 7.1±0.3** 6.61±0.07**
Gene expression values of four different ABC transporters in the human kidney,
mouse kidney, and rat kidney. ABCB1 is present in two different forms in rat and
mouse Abcb1a and Abcb1b, respectively. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal standard for normalization of gene
expression levels (CT values for GAPDH: human=22.3±0.9, mouse=19.8±0.3,
rat=16.06±0.04). *Po0.05 vs human kidney, **Po0.01 vs human kidney,
***Po0.001 vs human kidney.
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Figure 2 | Breast cancer resistance protein (BCRP/ABCG2)
expression in kidney and isolated human proximal tubular cells.
A representative PCR analysis (a) shows that a 206-bp fragment of
BCRP/ABCG2 was detected in human kidney cortex (lanes 4 and 5), in
human proximal tubule cell monolayers (lane 2), and mixed cell
monolayers (B80 proximal tubule cells/B20% cortical distal/
collecting duct cells) (lane 3) but not in purified distal/collecting duct
cell monolayers (lane 6). Lanes 1 and 7 represent negative controls.
Western blot analysis (b) shows that BCRP/ABCG2 was detected in
human kidney total membranes (lanes 1 and 2) and in isolated
human proximal tubular cells (lane 9). In rodents, BCRP/ABCG2 was
observed in total membranes isolated from rat kidney (lanes 3 and 4)
and mouse kidney (lanes 7 and 8). Membranes isolated from bcrp/
abcg2(/) kidney showed no BCRP/ABCG2 signal (lanes 5 and 6).
b-Actin expression was used to determine semiquantitative
BCRP/ABCG2 expression in four independent analyses (c). *Po0.05,
**Po0.01, compared to BCRP/ABCG2 expression in human kidney.
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a Hoechst 33342 efflux assay.15 As summarized in Figure 5,
dye retention by the cells in the presence of the specific
ABCG2 inhibitor fumitremorgin C (10 mM) was 2.36±0.03-
fold higher than in control monolayers. Further, in
the presence of nelfinavir (10 mM), an inhibitor of both
P-gp/ABCB1 and BCRP/ABCG2, the cellular retention of
Hoechst 33342 (1 mM) was 4.92±0.17-fold higher than
control values. These data are consistent with the inhibition
of BCRP/ABCG2-mediated Hoechst 33342 dye efflux across
the apical membrane of the proximal tubule cell monolayer.
Consistent with this, the amount of Hoechst 33342 appearing
in the apical media during the efflux period was substantially
less in the presence of inhibitors, for example, in the presence
of fumitremorgin C (FTC; 10 mM), the efflux of dye into the
apical compartment was 53±9% of the efflux rate in the
absence of inhibitor. In the presence of nelfinavir (10 mM), the
appearance of dye in the apical compartment was reduced to
33±8% of control values, reflecting both inhibition of
BCRP/ABCG2 and P-gp/ABCB1-mediated efflux.
DISCUSSION
In this study, we demonstrate for the first time expression,
localization, and transport activity of BCRP/ABCG2 in the
apical (brush border) membrane of human proximal tubules
using RQ-PCR, immunoblotting, immunohistochemical
analysis, and a functional Hoechst 33342 efflux assay. This
localization is in agreement with results obtained in mouse
kidney tissue8,11 and in rat kidney (present study). Previous
reports investigating the expression of BCRP/ABCG2 in
healthy human kidney used the antibody BXP-34,8 but
staining of the efflux pump was not obtained. In renal
carcinoma samples, the transporter protein was detectable
using a different antibody, BXP-21, but not with BXP-34.9,10
The reason for these controversial findings may be the
difference in antibodies used in these studies. BXP-34 was
obtained after immunization of mice with MCF-7/MR breast
cancer cells.10 The BXP-21 antibody, however, was obtained
after immunization of mice with a fusion protein of the
Escherichia coli maltose-binding protein with a 126-amino-
acid part of BCRP/ABCG2 (amino acids 271–396) directed
against an internal epitope before the first transmembrane
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Figure 3 | Immunofluorescent analysis of BCRP/ABCG2 in human,
rat, and mouse kidney. Representative immunohistochemical
images of BCRP/ABCG2 staining (in red) at the brush border
membranes of the proximal tubules in human kidney (a), rat kidney
(b), and mouse kidney (d). No staining was observed in bcrp/abcg2(/)
mice, serving as a negative control (c). Counterstaining (in green) was
performed with Naþ ,Kþ -ATPase, which is localized to the basolateral
membrane. G, glomerulus; PT, proximal tubule. Original
magnification  200.
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b
Figure 4 | Expression of BCRP/ABCG2 in human primary renal
tubule cell cultures. (a) Immunohistochemical staining of a
representative proximal tubule cell monolayer with BXP-9 antibody
shows extensive staining of the cell membrane. The XY section was
taken at the level of the apical membrane. (b) An XZ confocal image
of the monolayer (taken from the location indicated by the dotted
line in (a)) confirmed the localization of ABCG2 to the apical
membrane but also suggests some degree of subapical membrane
localization. Nuclei are counterstained with propidium iodide.
Bar¼ 10 mm.
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Figure 5 | Functional expression of BCRP/ABCG2 in human
proximal tubule cell monolayers. The cellular retention of 1 mM
Hoechst 33342 was measured in the presence and absence of either
10mM FTC or 10mM nelfinavir. Both efflux pump inhibitors resulted
in a significant (Po0.01 analysis of variance, Dunnet’s post-test)
increase in the cellular retention of Hoechst 3342. The data are
expressed as the mean±s.e. from four cell monolayers. **Po0.05,
compared to control.
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segment.9 We used a third antibody, BXP-9, which was
generated in rats with a fusion protein containing a fragment
of mouse bcrp protein corresponding to amino acids 221–394
and the E. coli maltose-binding protein (Kamiya Biomedical
Company). This antibody was also directed against an
internal epitope located just before the first transmembrane
segment. With the use of BXP-9, we could clearly detect and
localize BCRP/ABCG2 in healthy human kidney tissue. In
addition, we used the BXP-21 antibody to detect BCRP/
ABCG2 expression in monolayers of human proximal tubule
cells. In these primary cultures, we confirmed the apical
localization of the transporter protein. Using a functional
Hoechst 33342 efflux assay, we show for the first time
transport activity of BCRP/ABCG2 in human primary
proximal tubular cells, which can be inhibited by the specific
BCRP/ABCG2 inhibitor FTC and by nelfinavir.16 The
maximum inhibition of dye efflux by nelfinavir was B2-
fold greater than the maximum inhibition of dye efflux
generated by FTC, suggesting that at least part of the
nelfinavir inhibition of Hoechst 33342 dye efflux across the
apical membrane of the proximal tubule cells is mediated by
P-gp/ABCB1.17,18
Although its moderate expression levels may suggest a less
important role as an efflux pump in comparison with other
apical transporters, BCRP/ABCG2 can be highly influenced
and regulated by external factors and may have an important
function under pathological conditions as well as in the
transport of specific substrates. In mice, the absence of bcrp/
abcg2 causes a strong upregulation of abcg5 and abcg8 gene
expression in the kidney. This suggests a compensatory
mechanism further emphasizing the importance of the efflux
pump.
Epidermal growth factor (EGF), which is also associated
to proliferation and differentiation of multiple cell
types, regulates the expression of BCRP/ABCG2 via MAPK
cascade.19 Drugs that target the EGF pathway, like tyrosine
kinase inhibitors blocking the MAPK cascade, may, therefore,
increase the sensitivity to xenobiotics by increasing their
accumulation as a result of reduced transporter activity.20
Others showed that BCRP/ABCG2 expression is regulated by
IL-1b and TNF-a,21 and a role for endothelin-1, but not for
TNF-a, was found in rat brain capillaries.22 In addition, sex
hormones influence the expression levels of Bcrp.23 These
insights illustrate that BCRP/ABCG2 expression is highly
controlled under varying conditions by signaling pathways
that are also effective in regulating ABC transporter
expression in the kidney.5,24
In conclusion, we identified a new efflux transport protein
in the apical membrane of human kidney proximal tubules.
BCRP/ABCG2 likely contributes to the excretory processes of
drugs and toxic substances in the urine and has, in this way,
an important protective function. The relative importance of
BCRP/ABCG2 in the human kidney compared to other
transporters localized at the apical membrane of the proximal
tubules, for example, ABCB1/P-glycoprotein, ABCC2/MRP2,
and ABCC4/MRP4, remains to be determined.
MATERIALS AND METHODS
Tissues and primary cultures
Healthy human material used for RQ-PCR and western blot analysis
was obtained from the distant pole of kidneys removed for localized
malignancy. For immunohistochemistry, material was obtained
from donor kidneys not used for transplantation. Human tubular
epithelial cells were isolated as previously described25,26 and brought
into culture as pure cultures of either proximal tubular or distal
tubule/cortical collecting duct cells, or as a mixed population
comprising B80% proximal tubular and B20% distal tubule/
cortical collecting duct cells. In each case, cells were seeded directly
onto 6.5-mm to 0.4-mm pore size polycarbonate Transwell filter
supports (Costar Corning Inc., Acton, MA, USA) at a density of
50 000 cells per filter. Mixed and pure cultures of proximal tubular
cells and distal tubule cells were grown for 6–10 days on
polycarbonate Transwell filters (Costar) in a-MEM (Life Techno-
logies Inc., Rockville, MD, USA) modified according to Gibson
d’Ambrosio,27 supplemented with 10% fetal calf serum. For efflux
studies, cells were grown for 6–10 days on solid plastic supports. Cell
culture medium was replaced by Krebs’ solution (mmol l1): NaCl
140; KCl 5.4; MgSO4 1.2; KH2PO4 0.3; NaH2PO4 0.3; CaCl2 2;
glucose 5; Hepes 10 buffered to pH 7.4 at 371C with Tris base for
transport studies.
Quantitative real-time PCR
For RQ-PCR, two pooled samples obtained from 16 different mice,
three pooled samples from 9 different rats, and four samples from
human kidney were used. Primer probe sets were designed by
Applied Biosystems (Foster City, CA, USA). RQ-PCR was
performed in duplicates using the ABI/PRISM 7900 HT Gene
Expression Micro Fluidic Card, as described.11 The housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal standard. Data are expressed as delta cycle
threshold (DCT) values, indicating the relative ABCG2 expression
levels after correcting for the household gene GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase). High CT values indicate a low
expression of the gene in the sample, a low CT value indicates an
early detection of the fluorescence signal and represent a high gene
expression. To investigate expression of BCRP/ABCG2 in human
tubule cell monolayers, a qualitative RT-PCR approach was
employed.
Western blot analysis
For western blot analysis, renal total membrane fractions and
proximal tubule cells isolated from human urines were prepared
and isolated as described.11,14,28 Samples were solubilized in
DL-dithiothreitol and Laemmli sample buffer. After electrotransfer
of the proteins onto a nitrocellulose membrane, analysis was
performed by the Odyssey infrared imaging system (LI-COR;
Biosciences, Lincoln, NE, USA). The membrane was blocked in
Odyssey blocking buffer diluted 1:1 with PBS for 1 h at room
temperature. Subsequently, the membrane was incubated overnight
with the primary antibodies at 41C: BCRP/ABCG2 (BXP-9; Kamiya
Biomedical Company) diluted 1:200, b-actin (Sigma, Zwijndrecht,
The Netherlands) diluted 1:100 000 in PBS, 0.1% Tween 20, and
0.01% SDS. After three washing steps for 10 min in PBS, the blot
was incubated in the dark at room temperature for 60 min with the
secondary antibody in PBS, 0.1% Tween 20; IRDye 800 anti-rat, and
IRDye 800 anti-mouse (Rockland Immunohistochemistry Inc.,
Gilbertsville, PA, USA). The washing steps were repeated, after
which images were acquired with the Odyssey infrared imaging
224 Kidney International (2008) 73, 220–225
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system and analyzed by the software program as specified in the
Odyssey software manual.
Histological analysis
Frozen renal sections (1.5 mm) were stained for BCRP/ABCG2 and
Naþ ,Kþ -ATPase as reported previously.11 The primary antibodies
for BCRP/ABCG2 and Naþ ,Kþ -ATPase were diluted 1:50 and
1:1000, respectively. Human proximal tubule cells grown on
permeable filter supports for 8 days were fixed in 3% paraformal-
dehyde for 1 h before staining with the primary BCRP/ABCG2
antibody BXP-9 (Kamiya Biomedical Company, Seattle, WA, USA)
at a 1:120 dilution. The secondary antibody was rabbit/mouse FITC
at a dilution of 1:50. Nuclei were counterstained with propidium
iodide (Molecular Probes/Invitrogen, Breda, The Netherlands) at
5 mg ml1 for 5 min. Sections were examined with a confocal laser
scanning microscope (Leica Lasertechnik GmbH, Heidelberg,
Germany).
Functional assay of BCRP activity in human proximal tubule
cell monolayers
The functional activity of BCRP/ABCG2 expressed at the apical
membrane of human proximal tubule cell monolayers was assayed
using a Hoechst 33342 efflux assay. Cell monolayers of human
proximal tubule cells were incubated for 90 min at 371C in 0.5 ml
Krebs’ solution containing 1 mM Hoechst 33342 or 1 mM Hoechst
333342 plus either 10 mM FTC or 10 mM nelfinavir. At 90 min, the
uptake buffer was aspirated off, and the monolayers washed 3 in
ice-cold Krebs’ buffer. Cell monolayers were then incubated at 371C
for 30 min in 0.5 ml Krebs’ solution in the presence and absence of
FTC or nelfinavir. This short efflux period increased the sensitivity
of the assay. At the end of this period, cell monolayers were lysed
and the Hoechst 33342 content of the lysate was assayed on a Perkin
Elmer fluorimeter with an excitation wavelength of 350 nm and an
emission wavelength of 480 nm.
Data analysis
Data are given as means±s.e. Mean values were considered to be
significantly different when Po0.05 by use of a Student’s t-test.
Software used for statistical analysis was GraphPad Prism (version
4.03 for Windows; Graph Pad Software, San Diego, CA, USA).
ACKNOWLEDGMENTS
This study was supported by a grant from the Dutch Kidney
Foundation (C02.2012) and Kidney Research UK (RP41/1/2005).
We thank Janny Peters for her analytical support.
REFERENCES
1. Krishnamurthy P, Ross DD, Nakanishi T et al. The stem cell marker
Bcrp/ABCG2 enhances hypoxic cell survival through interactions with
heme. J Biol Chem 2004; 279: 24218–24225.
2. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2)
in drug transport. AAPS J 2005; 7: E118–E133.
3. van Herwaarden AE, Wagenaar E, Merino G et al. Breast cancer resistance
protein (BCRP/ABCG2) secretes riboflavin (vitamin B2) into milk. Mol Cell
Biol 2007; 27: 1247–1253.
4. Chen ZS, Robey RW, Belinsky MG et al. Transport of methotrexate,
methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-
glucuronide) by ABCG2: effects of acquired mutations at R482 on
methotrexate transport. Cancer Res 2003; 63: 4048–4054.
5. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of
P-glycoprotein MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Toxicol Appl Pharmacol 2005; 204: 216–237.
6. Jonker JW, Merino G, Musters S et al. The breast cancer resistance protein
BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.
Nat Med 2005; 11: 127–129.
7. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer
resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340–7358.
8. Maliepaard M, Scheffer GL, Faneyte IF et al. Subcellular localization and
distribution of the breast cancer resistance protein transporter in normal
human tissues. Cancer Res 2001; 61: 3458–3464.
9. Diestra JE, Scheffer GL, Catala I et al. Frequent expression of the multi-
drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human
tumours detected by the BXP-21 monoclonal antibody in paraffin-
embedded material. J Pathol 2002; 198: 213–219.
10. Scheffer GL, Maliepaard M, Pijnenborg AC et al. Breast cancer resistance
protein is localized at the plasma membrane in mitoxantrone- and
topotecan-resistant cell lines. Cancer Res 2000; 60: 2589–2593.
11. Huls M, van den Heuvel JJ, Dijkman HB et al. ABC transporter expression
profiling after ischemic reperfusion injury in mouse kidney. Kidney Int
2006; 69: 2186–2193.
12. Jonker JW, Buitelaar M, Wagenaar E et al. The breast cancer resistance
protein protects against a major chlorophyll-derived dietary phototoxin
and protoporphyria. Proc Natl Acad Sci USA 2002; 99: 15649–15654.
13. Brown CDA, Windass A, Sayer R. Primary cultures of Human renal
proximal tubules as a model of renal xenobiotic secretion. AAPS J 2006; 8.
14. Wilmer MJ, Graaf-Hess A, Blom HJ et al. Elevated oxidized glutathione in
cystinotic proximal tubular epithelial cells. Biochem Biophys Res Commun
2005; 337: 610–614.
15. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an
efficient Hoechst 33342 efflux pump and is preferentially expressed by
immature human hematopoietic progenitors. Blood 2002; 99: 507–512.
16. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP
binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55:
3–29.
17. Choo EF, Leake B, Wandel C et al. Pharmacological inhibition of
P-glycoprotein transport enhances the distribution of HIV-1 protease
inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655–660.
18. Schwab D, Fischer H, Tabatabaei A et al. Comparison of in vitro
P-glycoprotein screening assays: recommendations for their use in
drug discovery. J Med Chem 2003; 46: 1716–1725.
19. Meyer zu Schwabedissen HE, Grube M, Dreisbach A et al. Epidermal
growth factor-mediated activation of the map kinase cascade results in
altered expression and function of ABCG2 (BCRP). Drug Metab Dispos
2006; 34: 524–533.
20. Leggas M, Panetta JC, Zhuang Y et al. Gefitinib modulates the function of
multiple ATP-binding cassette transporters in vivo. Cancer Res 2006; 66:
4802–4807.
21. Evseenko DA, Paxton JW, Keelan JA. Independent regulation of apical and
basolateral drug transporter expression and function in placental
trophoblasts by cytokines, steroids and growth factors. Drug Metab
Dispos 2007; 35: 595–601.
22. Bauer B, Hartz AM, Miller DS. TNF-{alpha} and endothelin-1 increase
P-glycoprotein expression and transport activity at the blood–brain
barrier. Mol Pharmacol 2007; 71: 667–675.
23. Tanaka Y, Slitt AL, Leazer TM et al. Tissue distribution and hormonal
regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats
and mice. Biochem Biophys Res Commun 2005; 326: 181–187.
24. van de Water FM, Masereeuw R, Russel FG. Function and regulation of
multidrug resistance proteins (MRPs) in the renal elimination of organic
anions. Drug Metab Rev 2005; 37: 443–471.
25. Helbert MJ, Dauwe S, De Broe ME. Flow cytometric immunodissection of
the human nephron in vivo and in vitro. Exp Nephrol 1999; 7: 360–376.
26. Helbert MJ, Dauwe SE, Van der Biest I et al. Immunodissection of the
human proximal nephron: flow sorting of S1S2S3, S1S2 and S3 proximal
tubular cells. Kidney Int 1997; 52: 414–428.
27. Gibson-D’Ambrosio RE, Samuel M, Chang CC et al. Characteristics of
long-term human epithelial cell cultures derived from normal human
fetal kidney. In Vitro Cell Dev Biol 1987; 23: 279–287.
28. Russel FG, van der Linden PE, Vermeulen WG et al. Na+ and H+ gradient-
dependent transport of p-aminohippurate in membrane vesicles from
dog kidney cortex. Biochem Pharmacol 1988; 37: 2639–2649.
Kidney International (2008) 73, 220–225 225
M Huls et al.: ABCG2 is expressed in the human kidney proximal tubule o r i g i n a l a r t i c l e
